Strategy and Product in Biotechnology | Persian Bio

Introducing the Strategy and Product in Biotechnology Column: Why We Are Writing It

A brilliant scientific idea rarely becomes a product on its own. Between the laboratory bench and the market lies a gap that no microscope can reveal, yet every year projects, teams, and investors pay for it. Strategy and Product in Biotechnology is the new column of the Persian Bio blog, and it starts from exactly this gap. This article introduces the column, explains why we decided to write it, who it is for, and which paths it will follow. If you have ever wondered why some promising biological technologies never reach patients or customers, keep reading. The answer is more interesting than you might expect.

Why Biotechnology Needs a Product Strategy

Biotechnology has long moved at a pace that is both remarkable and, for those who must justify budgets, occasionally exhausting. A sophisticated algorithm, a robust predictive model, or a stable data pipeline still leaves three questions open: Which user problem does this solve? How do we measure its value? And through which business model does it reach the end user?

Product strategy turns these questions into concrete decisions. Which component of the platform comes first? Which market is the priority? When does a pilot become a commercial product? Which metrics define success, rather than simply looking impressive in a slide deck? In biotechnology these decisions are harder than in most industries. Development cycles are long, regulatory requirements are strict, and the buyer is rarely the same person who uses the product every day. A researcher, a hospital, a pharmaceutical company, and a finance director each speak a different language, and someone has to translate between them.

Let us be honest: a product built without strategy is often a well-intentioned scientific project that forgot someone has to buy it, use it, and come back to it. Elegant code and precise models are necessary conditions. They are not sufficient ones. Nobody has ever secured a budget renewal by citing an elegant pipeline alone.

The Gap Between Science and Market

In technical literature, model accuracy and rigorous validation rightly come first. In practice, however, many biological projects stall not because of scientific weakness but in the later stages: no clear economic model, no defined route to market, an inability to explain value to non-technical decision-makers, or poor planning for scale. The gap is rarely visible, because each side assumes the other is doing the critical work.

Consider a hypothetical example. A team builds a precise method for analyzing immune response that performs flawlessly in the lab. If it does not know which biomarker a clinician or pharmaceutical company needs for adoption, or what it would cost to run the method in a hospital, the tool will never leave the research phase. Scientific quality is the entry ticket, not a guarantee of staying in the game.

Software engineers and distributed-systems architects face a different set of questions. Which parts of the system must scale? How is sensitive data protected? When should a research script become a reliable service? Answering these requires an understanding of both the scientific logic and the regulatory context of biotechnology. This column was shaped at exactly that intersection.

Why Now?

A few years ago, much of biotechnology activity was concentrated in laboratories and research centers, and business questions were largely postponed. That distance has shrunk. Biological data is being generated in far greater volumes, artificial intelligence tools have entered research workflows, and investment decisions are being made earlier than before. Product thinking is therefore no longer a decorative choice; it has become part of the decision infrastructure. This column begins at this point of change, with the aim of documenting and analyzing it as it unfolds.

Two Columns, One Direction

The Persian Bio blog launches with two aligned columns. This column approaches topics from the perspective of management and business, covering health economics, growth models, and the Bio-IT ecosystem. The technical column, written by our Chief Technology Officer (CTO), speaks from the engineering core of the company and examines implementation, architecture, and the evaluation of algorithms.

The two columns complement each other. A strategic decision without technical understanding is wishful thinking, and technical implementation without strategic direction is effort without a destination. To see how the technical side of this work is framed, start with the introductory article of the technical column (in Persian). It shows how immunoinformatics, data engineering, and software development meet in practice.

Topics We Will Cover

Health economics: how a biological solution becomes a measurable outcome for healthcare systems and patients.

Growth models: the routes from laboratory idea to market, and the decision points along each.

Product strategy for biological data: turning complex data into a product that is sellable, reliable, and explainable.

The Bio-IT ecosystem: players, partnerships, and competition at the boundary of biology and information technology.

Decision reviews: analysis of decisions that worked and those that did not, written with the transparency expected of an engineering column.

Every article follows a clear structure: a well-defined problem, the context a reader needs, analysis of the decisions involved, and claims that can be tested. Rather than slogans, we will state assumptions explicitly so readers can challenge them. This is useful for a product manager and equally for a researcher who wants to understand why an idea failed to survive contact with the market.

Who This Column Is For

This column is written for founders and managers of biotechnology startups facing difficult product choices; for researchers who want to turn scientific results into value that markets can understand; for investors and analysts seeking to understand the growth logic of the field; and for students who want to see where science and business meet before entering the workforce. If you see yourself in any of these groups, this column was written with you in mind.

Conclusion and Call to Action

In closing, this column will address questions that rarely appear in scientific papers but have the greatest influence on the fate of a technology. We will write openly, about successes and also about decisions that did not work out, because trust in this field is built on that transparency.

If there is a topic you think deserves examination in the Strategy and Product in Biotechnology column, send it to us. And if you found this introduction useful, share it with colleagues who work at the boundary of science and business.